RT Journal Article
SR Electronic
T1 Postpartum Tubal Sterilization in Sickle Cell Disease in the 2012-2019 National Inpatient Sample
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.30.24314263
DO 10.1101/2024.09.30.24314263
A1 Luo, Amy
A1 Gemmill, Alison
A1 Scott, Jayla L
A1 Burke, Anne E.
A1 Pecker, Lydia H.
YR 2024
UL http://medrxiv.org/content/early/2024/10/01/2024.09.30.24314263.abstract
AB Importance Sickle cell disease (SCD) is associated with high-risk pregnancy and low rates of hormonal contraception use. Intersectional vulnerabilities among individuals with SCD in the United States (US) raise historically and socially contingent questions about tubal sterilization in individuals with SCD. However immediate postpartum tubal sterilization (TS) rates among individuals with SCD in the US are unknown.Objective To compare rates of TS in deliveries to people with SCD and without SCD, and to determine the modifying effect of severe maternal morbidity (SMM) on the odds of TS.Design, Setting, and Participants This repeated cross-sectional study used the 2012-2019 National Inpatient Sample to estimate the rate of TS among delivery hospitalizations to people with SCD, without SCD (non-SCD), Black people with and without SCD, and people with cystic fibrosis (CF). Logistic regression models estimated the odds of TS between SCD and non-SCD deliveries, SCD and non-SCD deliveries with Black race, and SCD and CF deliveries. We examined whether SMM modified the association between TS and SCD in interaction analyses.Exposure SCD, CFResults Among 29,822,518 deliveries, 6.7% underwent TS. Among 18,860 SCD deliveries, 8.8% underwent TS. Among 2,945 CF deliveries, 6.6% underwent TS. After adjusting for patient and hospital characteristics, SCD had higher odds of TS compared to non-SCD deliveries (aOR= 1.38 [1.06,1.79]) and in a stratified analysis of deliveries coded with Black race (aOR= 1.42 [1.06,1.90]). After adjusting for patient and hospital characteristics, there was no difference in the odds of TS between SCD or CF deliveries (aOR=1.0 [0.51,2.24]). SMM more than doubled the odds of TS in SCD deliveries (interaction: aOR=2.34 [1.57,3.47]; aOR= 2.14 [1.40,3.24] in deliveries coded with Black race).Conclusion Even after accounting for patient and hospital characteristics, people with SCD have higher odds of immediate postpartum TS compared to control groups. SMM at delivery increased the odds of TS in SCD compared to all non-SCD deliveries and compared to CF deliveries. Possibly SMM severity, patient preference, or clinician recommendations inform this finding. SMM is 3-7 times more common in SCD than non-SCD pregnancies and may be a modifiable risk factor for TS in SCD deliveries.Question What are the national rates and associations of postpartum tubal sterilization (TS) among deliveries to people with sickle cell disease (SCD) compared to deliveries to people without SCD (non-SCD) and cystic fibrosis (CF)?Findings From 2012-2019, the TS rate was significantly higher in SCD deliveries (88 per 1,000 deliveries) vs non-SCD (67 per 1,000 deliveries) and CF deliveries (66 per 1,000 deliveries). SCD was positively associated with TS. SMM modified the association between TS and SCD by two-fold.Meaning Postpartum TS rate in people with SCD is high; SMM during SCD deliveries significantly increases the odds of postpartum TS.Competing Interest StatementAEB received research funding from Merck, Exeltis, Dare, and NICHD, all mediated through Johns Hopkins University, and honorarium for Exeltis Advisory Board. LHP served as a consultant for Global Blood Therapeutics and Novo Nordisk and is the co-founder of the Sickle Cell Reproductive Health Education Directive. AL, AG, & JLS have no disclosures to report.Funding StatementData analysis was supported by Boston Globe Media. AL was supported on a NIMH training grant (T32MH122357). LHP is funded by the NIH, the American Society of Hematology, Doris Duke Charitable Foundation, the Mellon Foundation, and Alexion. AG is funded by the NIH, the NSF, and the Society of Family Planning. The funders had no role in the analysis or writing of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used are available from the Agency for Healthcare Research and Quality and Healthcare Cost and Utilization Project 2012-2019 National Inpatient Sample (https://hcup-us.ahrq.gov/nisoverview.jsp).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are managed by the Agency for Healthcare Research and Quality and is only available through registration with this entity and completion of their required training module. For more information on accessing HCUP data visit www.hcup-us.ahrq.gov. https://hcup-us.ahrq.gov/ https://hcup-us.ahrq.gov/nisoverview.jsp 95% CI95% Confidence IntervalaORAdjusted Odds RatioCFCystic FibrosisICDInternational Classification of DiseaseICD-10-CM/PCSInternational Classification of Disease, Tenth Revision, Clinical Modification and International Classification of Disease, Tenth Revision, Procedural Coding SystemICD-9-CM/PCSInternational Classification of Disease, Ninth Revision, Clinical Modification and International Classification of Disease, Ninth Revision, Procedural Coding SystemNISNational Inpatient SampleOROdds RatioRDRate DifferenceSCDSickle Cell DiseaseSMMSevere Maternal MorbidityTSTubal Sterilization during the Immediate Postpartum PeriodUSUnited States